NASDAQ:SRTS - Sensus Healthcare Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.33
  • Forecasted Upside: 18.28 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$6.20
+0.30 (1.20%)

This chart shows the closing price for SRTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sensus Healthcare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRTS

Analyst Price Target is $7.33
▲ +18.28% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sensus Healthcare in the last 3 months. The average price target is $7.33, with a high forecast of $9.00 and a low forecast of $6.00. The average price target represents a 18.28% upside from the last price of $6.20.

This chart shows the closing price for SRTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Sensus Healthcare. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/5/2021Maxim GroupReiterated RatingBuy$7.00Medium
11/5/2021HC WainwrightBoost Price TargetBuy$7.00 ➝ $9.00High
8/6/2021HC WainwrightBoost Price TargetBuy$6.00 ➝ $7.00High
5/7/2021Maxim GroupReiterated RatingBuy$6.00Medium
3/1/2021HC WainwrightBoost Price TargetBuy$4.00 ➝ $6.00Low
2/26/2021Roth CapitalBoost Price TargetBuy$4.00 ➝ $6.00High
2/26/2021Northland SecuritiesUpgradeMarket Perform ➝ OutperformHigh
12/16/2020Northland SecuritiesDowngradeOutperform ➝ Market PerformHigh
11/9/2020HC WainwrightLower Price TargetBuy$5.00 ➝ $4.00High
11/6/2020Maxim GroupReiterated RatingBuy$6.00High
8/10/2020Alliance Global PartnersUpgradeNeutral ➝ Buy$2.40 ➝ $4.25High
8/7/2020HC WainwrightReiterated RatingBuy$5.00Low
6/4/2020Northland SecuritiesInitiated CoverageBuy$4.65Low
5/11/2020B. RileyLower Price TargetNeutral$5.50 ➝ $3.00Medium
5/8/2020Maxim GroupReiterated RatingBuy$6.00Medium
5/8/2020HC WainwrightLower Price TargetBuy$8.00 ➝ $5.00Medium
5/6/2020Alliance Global PartnersDowngradeBuy ➝ Neutral$6.00 ➝ $2.40High
2/14/2020Alliance Global PartnersUpgradeNeutral ➝ Buy$6.00High
2/14/2020HC WainwrightLower Price TargetBuy$10.00 ➝ $8.00Medium
11/7/2019B. RileyDowngradeBuy ➝ Neutral$14.00 ➝ $5.50High
11/7/2019HC WainwrightReiterated RatingBuy$10.00High
8/9/2019Maxim GroupSet Price TargetBuy$11.00Medium
5/13/2019HC WainwrightReiterated RatingBuy$9.00High
5/10/2019Maxim GroupReiterated RatingBuy$11.00High
5/10/2019Alliance Global PartnersDowngradeBuy ➝ NeutralHigh
2/19/2019Roth CapitalReiterated RatingBuyMedium
2/15/2019Northland SecuritiesReiterated RatingSell$5.00Low
1/29/2019Northland SecuritiesDowngradeMarket Perform ➝ Under PerformHigh
12/11/2018Craig HallumInitiated CoverageBuy$10.00Medium
10/15/2018Northland SecuritiesDowngradeOutperform ➝ Market PerformHigh
9/26/2018B. RileyInitiated CoverageBuy$12.50Medium
9/19/2018Maxim GroupBoost Price TargetBuy$9.00 ➝ $10.00Low
8/27/2018HC WainwrightInitiated CoverageBuy$14.00High
8/1/2018Roth CapitalInitiated CoverageBuy$12.50High
2/2/2018Maxim GroupBoost Price TargetBuy ➝ Buy$7.50 ➝ $9.00Medium
11/3/2017Maxim GroupBoost Price TargetBuy ➝ Buy$6.50 ➝ $7.50N/A
6/6/2017Maxim GroupInitiated CoverageBuy ➝ Buy$6.50High
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 6 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 6 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Sensus Healthcare logo
Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
Read More

Today's Range

Now: $6.20
Low: $6.13
High: $6.30

50 Day Range

MA: $4.25
Low: $3.51
High: $6.20

52 Week Range

Now: $6.20
Low: $2.90
High: $6.30

Volume

185,943 shs

Average Volume

174,695 shs

Market Capitalization

$103.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Sensus Healthcare?

The following Wall Street sell-side analysts have issued reports on Sensus Healthcare in the last twelve months: HC Wainwright, Maxim Group, Northland Securities, Roth Capital, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for SRTS.

What is the current price target for Sensus Healthcare?

3 Wall Street analysts have set twelve-month price targets for Sensus Healthcare in the last year. Their average twelve-month price target is $7.33, suggesting a possible upside of 18.3%. HC Wainwright has the highest price target set, predicting SRTS will reach $9.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $6.00 for Sensus Healthcare in the next year.
View the latest price targets for SRTS.

What is the current consensus analyst rating for Sensus Healthcare?

Sensus Healthcare currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRTS will outperform the market and that investors should add to their positions of Sensus Healthcare.
View the latest ratings for SRTS.

What other companies compete with Sensus Healthcare?

How do I contact Sensus Healthcare's investor relations team?

Sensus Healthcare's physical mailing address is 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487. The company's listed phone number is (561) 922-5808 and its investor relations email address is [email protected] The official website for Sensus Healthcare is www.sensushealthcare.com.